A citation-based method for searching scientific literature

Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M Kirkwood. N Engl J Med 2017
Times Cited: 641







List of co-cited articles
522 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
975
66

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino,[...]. N Engl J Med 2018
739
60

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur,[...]. CA Cancer J Clin 2017
839
38

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Mark B Faries, John F Thompson, Alistair J Cochran, Robert H Andtbacka, Nicola Mozzillo, Jonathan S Zager, Tiina Jahkola, Tawnya L Bowles, Alessandro Testori, Peter D Beitsch,[...]. N Engl J Med 2017
570
34

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. N Engl J Med 2016
738
25

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
21

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. Lancet Oncol 2015
711
20

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
334
19

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
19

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Klaus-Werner Schulte, Percy Lehmann,[...]. Lancet Oncol 2016
326
19

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. J Clin Oncol 2018
112
17

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
326
17

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
842
17

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni,[...]. Lancet Oncol 2020
68
25

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
16

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
16

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
15

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M Kirkwood, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. N Engl J Med 2020
48
31

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
14

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
14

Final version of 2009 AJCC melanoma staging and classification.
Charles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, John F Thompson, Michael B Atkins, David R Byrd, Antonio C Buzaid, Alistair J Cochran, Daniel G Coit, Shouluan Ding,[...]. J Clin Oncol 2009
14

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob,[...]. Lancet 2015
771
13

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
471
13

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
13

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
13

Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
Donald L Morton, John F Thompson, Alistair J Cochran, Nicola Mozzillo, Omgo E Nieweg, Daniel F Roses, Harold J Hoekstra, Constantine P Karakousis, Christopher A Puleo, Brendon J Coventry,[...]. N Engl J Med 2014
774
13

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.
Jeffrey E Gershenwald, Richard A Scolyer. Ann Surg Oncol 2018
147
13

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Christian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, Karolina Sikorska, Bart van de Wiel, Pia Kvistborg, Oscar Krijgsman, Marlous van den Braber, Daisy Philips, Annegien Broeks,[...]. Nat Med 2018
264
12

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
12

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
12

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
215
12

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo Antonio Ascierto, Jon M Richards,[...]. Eur J Cancer 2019
55
21

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, Chandra Adhikari, Carolien Bierman, Bart A van de Wiel, Richard A Scolyer, Oscar Krijgsman, Karolina Sikorska, Hanna Eriksson,[...]. Lancet Oncol 2019
137
12

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino,[...]. J Clin Oncol 2020
49
24

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, Michael A Davies, Merrick I Ross, Isabella C Glitza, Janice N Cormier, Carol Lewis, Wen-Jen Hwu, Ehab Hanna,[...]. Nat Med 2018
291
11

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi,[...]. Lancet Oncol 2018
125
11

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona M McNeil, Michal Lotem,[...]. Lancet Oncol 2019
312
11

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski,[...]. Lancet Oncol 2018
94
10

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day, Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-François Baurain, Alessandro Testori, Jean-Jacques Grob,[...]. N Engl J Med 2011
10

Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long. Nat Rev Clin Oncol 2017
530
10


Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert H Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Kerstin Schatton, Percy Lehmann,[...]. J Clin Oncol 2019
52
19

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Alexander C Huang, Robert J Orlowski, Xiaowei Xu, Rosemarie Mick, Sangeeth M George, Patrick K Yan, Sasikanth Manne, Adam A Kraya, Bradley Wubbenhorst, Liza Dorfman,[...]. Nat Med 2019
203
10

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev V Demidov, Jessica C Hassel, Piotr Rutkowski, Peter Mohr,[...]. N Engl J Med 2012
9

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Daniel G Coit, John A Thompson, Mark R Albertini, Christopher Barker, William E Carson, Carlo Contreras, Gregory A Daniels, Dominick DiMaio, Ryan C Fields, Martin D Fleming,[...]. J Natl Compr Canc Netw 2019
161
9

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, Omid Hamid, F Stephen Hodi, Stergios J Moschos, Nikhil I Khushalani, Karl Lewis, Christopher D Lao, Michael A Postow,[...]. N Engl J Med 2018
488
9

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov,[...]. Lancet 2020
114
9

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A Delman, Lynn E Spitler, Igor Puzanov, Sanjiv S Agarwala,[...]. J Clin Oncol 2015
8

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. Lancet 2017
577
8

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Matteo S Carlino, Rosalie Fisher, Georgina V Long, F Stephen Hodi, Jennifer Tsoi,[...]. Nat Med 2019
127
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.